Embecta outperforms its own revenue estimates with $566M in first 6 months of BD spinout

It can be difficult for a spinout to distinguish itself from its parent company—especially if that company has been around for a century. Just ask Embecta CEO Devdatt Kurdikar, Ph.D., who discussed the slow process of emerging from BD’s shadow in an interview with Fierce Medtech earlier this year, only a few weeks after the diabetes devicemaker had left the nest.

error: Content is protected !!